These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6676042)

  • 21. The prognostic value of cell surface antigens in low grade, non-invasive, transitional cell carcinoma of the bladder.
    Young AK; Hammond E; Middleton AW
    J Urol; 1979 Oct; 122(4):462-4. PubMed ID: 480485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue blood group ABH and Thomsen-Friedenreich antigens in human urinary bladder carcinoma.
    Weinstein RS; Miller AW; Coon JS
    Prog Clin Biol Res; 1984; 153():249-60. PubMed ID: 6382282
    [No Abstract]   [Full Text] [Related]  

  • 23. Blood group antigens in transitional cell tumours of the urinary bladder. An immunohistochemical study.
    Juhl BR
    Dan Med Bull; 1994 Feb; 41(1):1-11. PubMed ID: 8187557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood group antigens and bladder cancer.
    Bishop MC
    Br Med J (Clin Res Ed); 1982 May; 284(6327):1426-7. PubMed ID: 6805549
    [No Abstract]   [Full Text] [Related]  

  • 25. Bladder tumors: when to do and what to expect from random mucosal biopsies with reference to blood group cell surface antigens.
    Boccon-Gibod L; Boccon-Gibod L; Desligneres S; Janin-Mercier A
    Eur Urol; 1987; 13(1-2):1-6. PubMed ID: 3582436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Luminal epithelial antigen (LEA.135) expression correlates with tumor progression for transitional carcinoma of the bladder.
    Jones HL; Delahunt B; Bethwaite PB; Thornton A
    Anticancer Res; 1997; 17(1B):685-7. PubMed ID: 9066602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Erythrocyte adherence test for identifying A, B and O(H) antigens in preneoplastic and neoplastic lesions of the bladder urothelium].
    Bertoni F; Mattarozzi A; Bacchini P
    Pathologica; 1982; 74(1032):449-61. PubMed ID: 7162862
    [No Abstract]   [Full Text] [Related]  

  • 28. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer.
    Kwak C; Ku JH; Park JY; Lee E; Lee SE; Lee C
    J Urol; 2004 Jan; 171(1):149-52. PubMed ID: 14665864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood group isoantigens and bladder cancer. An overview.
    Srinivas V; Khan SA
    Urol Int; 1985; 40(4):233-4. PubMed ID: 3901475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
    Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
    Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell surface A, B, or O(H) blood group antigens as an indicator of malignant potential in stage A bladder carcinoma.
    Newman AJ; Carlton CE; Johnson S
    J Urol; 1980 Jul; 124(1):27-9. PubMed ID: 7411715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The prognostic significance of the immune status (DNCB-test) in patients with carcinoma of the bladder, checked by observation of the course of disease (author's transl)].
    Flamm J; Burkert S
    Wien Med Wochenschr; 1981; 131(13-14):339-43. PubMed ID: 7281701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A B H isoantigens in bladder cancer. Preliminary study].
    Hernáez Manrique I; Rodríguez Trinidad A; Gastaminza A; Recarte Mendiluce JM
    Actas Urol Esp; 1983; 7(2):113-6. PubMed ID: 6880907
    [No Abstract]   [Full Text] [Related]  

  • 34. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
    Brake M; Loertzer H; Horsch R; Keller H
    J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of blood group antigens and carcinoembryonic antigen in urinary bladder carcinoma.
    Fujioka T; Ohhori T; Lovrekovich L; deKernion JB
    Urol Int; 1986; 41(6):397-402. PubMed ID: 3547992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The distribution of ABO-(H) isoantigens in tumors of the bladder].
    Baranyay F; Enzsöl C; Somogyi L
    Morphol Igazsagugyi Orv Sz; 1987 Apr; 27(2):123-7. PubMed ID: 3587245
    [No Abstract]   [Full Text] [Related]  

  • 37. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB; Zeng FH; Sun ZQ
    Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of specific red-cell adherence and immunoperoxidase staining techniques for ABO(H) blood-group cell-surface antigens on superficial transitional cell carcinoma of the bladder.
    Boileau MA; Cowles RS; Schmidt KL; Schmidt WA
    J Surg Oncol; 1985 Oct; 30(2):72-9. PubMed ID: 3908825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.